Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Front Immunol. 2023 Mar 15;14:1128151. doi: 10.3389/fimmu.2023.1128151. eCollection 2023.
Malignant glioma is the most frequent primary tumor of the central nervous system. PDCL3 is a member of the phosducin-like protein family, and its imbalance has been shown to be associated with several human diseases. However, the underlying role of PDCL3 in human malignant cancers, especially in malignant gliomas, is unclear. In this study, we combined public database analysis and experimental verification to explore the differential expression, prognostic value and potential functions and mechanisms of PDCL3. The results revealed that PDCL3 is upregulated in multiple cancers and acts as a potential prognostic biomarker of glioma. Mechanistically, PDCL3 expression is associated with epigenetic modifications and genetic mutations. PDCL3 may directly interact with the chaperonin-containing TCP1 complex, regulating cell malignancy, cell communication and the extracellular matrix. More importantly, the association of PDCL3 with the infiltration of immune cells, immunomodulatory genes, immune checkpoints, cancer stemness and angiogenesis suggested that PDCL3 may regulate the glioma immune landscape. Furthermore, PDCL3 interference also decreased the proliferation, invasion and migration of glioma cells. In conclusion, PDCL3 is a novel oncogene and can be adopted as a biomarker with value in assisting clinical diagnosis, predicting patient outcomes and assessing the immune landscape of the tumor microenvironment in glioma.
恶性神经胶质瘤是中枢神经系统最常见的原发性肿瘤。PDCL3 是磷脒丁氨酸类似蛋白家族的一员，其失衡已被证明与多种人类疾病有关。然而，PDCL3 在人类恶性肿瘤中的潜在作用，特别是在恶性神经胶质瘤中的作用尚不清楚。在这项研究中，我们结合公共数据库分析和实验验证，探讨了 PDCL3 的差异表达、预后价值以及潜在的功能和机制。结果表明，PDCL3 在多种癌症中上调，可作为胶质瘤的潜在预后生物标志物。从机制上讲，PDCL3 的表达与表观遗传修饰和基因突变有关。PDCL3 可能直接与包含热休克蛋白 10 同源物的 TCP1 复合物相互作用，调节细胞恶性程度、细胞通讯和细胞外基质。更重要的是，PDCL3 与免疫细胞浸润、免疫调节基因、免疫检查点、癌症干性和血管生成的关联表明，PDCL3 可能调节神经胶质瘤的免疫微环境。此外，PDCL3 干扰也降低了神经胶质瘤细胞的增殖、侵袭和迁移。总之，PDCL3 是一种新的癌基因，可以作为一种有价值的生物标志物，辅助临床诊断、预测患者预后，并评估肿瘤微环境的免疫景观。
